Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Goto, Toshihiro ^a,b   Itoh, Michiko ^a   Suganami, Takayoshi ^c   Kanai, Sayaka ^a   Shirakawa, Ibuki ^a   Sakai, Takeru ^a   Asakawa, Masahiro ^a   Yoneyama, Toshihiro ^b   Kai, Toshihiro ^b   Ogawa, Yoshihiro ^a,c,d,e  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; MC4R PROTEIN, MOUSE; MELANOCORTIN 4 RECEPTOR; OBETICHOLIC ACID; PROTEIN P53;

ANIMAL; BODY WEIGHT; C57BL MOUSE; CELL DEATH; CELL PROTECTION; COMPLICATION; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; GENE KNOCKOUT; GENETICS; INSULIN RESISTANCE; LIVER CELL; LIVER CIRRHOSIS; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY;

ANIMALS; BODY WEIGHT; CELL DEATH; CHENODEOXYCHOLIC ACID; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE KNOCKOUT TECHNIQUES; HEPATOCYTES; INSULIN RESISTANCE; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85047817579     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-26383-8     Document Type: Article

References (49)

1. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10, 627-636, https://doi.org/10.1038/nrgastro.2013.149 (2013).
2. Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330-344, https://doi.org/10.1038/nrgastro.2013.41 (2013).
3. Levene, A. P. & Goldin, R. D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152, https://doi.org/10.1111/j.1365-2559.2011.04145.x (2012).
4. Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437-443 (2003).
5. Chalasani, N. et al. The diagnosis and management of non-Alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005-2023, https://doi.org/10.1002/hep.25762 (2012).
6. Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693 (1995).
7. Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 101, 3668-3673, https://doi.org/10.1073/pnas.0400046101 (2004).
8. Sinal, C. J. et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell 102, 731-744, https://doi.org/10.1016/S0092-8674(00)00062-3 (2000).
9. Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-Alcoholic steatohepatitis. J Hepatol 51, 380-388, https://doi.org/10.1016/j.jhep.2009.03.025 (2009).
10. Bjursell, M. et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 8, e64721, https://doi.org/10.1371/journal.pone.0064721 (2013).
11. Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45, 3569-3572 (2002).
12. Haczeyni, F. et al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity 25, 155-165, https://doi.org/10.1002/oby.21701 (2017).
13. Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-Talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 292, 11055-11069, https://doi.org/10.1074/jbc.M117.784322 (2017).
14. Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51, 771-784, https://doi.org/10.1194/jlr.M001602 (2010).
15. Rodrigues, P. M. et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 8, e2748, https://doi.org/10.1038/cddis.2017.172 (2017).
16. Fiorucci, S. et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314, 584-595, https://doi.org/10.1124/jpet.105.084905 (2005).
17. Verbeke, L. et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 6, 33453, https://doi.org/10.1038/srep33453 (2016).
18. Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512 (2004).
19. Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e571, https://doi.org/10.1053/j.gastro.2013.05.042 (2013).
20. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965, https://doi.org/10.1016/S0140-6736(14)61933-4 (2015).
21. Nevens, F. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 375, 631-643, https://doi.org/10.1056/NEJMoa1509840 (2016).
22. Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454-2463, https://doi.org/10.1016/j.ajpath.2011.07.014 (2011).
23. Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493-505, https://doi.org/10.1016/j.cell.2005.08.035 (2005).
24. Itoh, M. et al. Hepatic crown-like structure: A unique histological feature in non-Alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https://doi.org/10.1371/journal.pone.0082163 (2013).
25. Komiya, C. et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 7, 44754, https://doi.org/10.1038/srep44754 (2017).
26. Konuma, K. et al. Eicosapentaenoic acid ameliorates non-Alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One 10, e0121528, https://doi.org/10.1371/journal.pone.0121528 (2015).
27. Yoshimura, K. et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 63, 462-473, https://doi.org/10.1002/hep.28226 (2016).
28. Castro, R. E. et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-Alcoholic fatty liver disease. J Hepatol 58, 119-125, https://doi.org/10.1016/j.jhep.2012.08.008 (2013).
29. Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-Alcoholic fatty liver disease. J Hepatol 58, 785-791, https://doi.org/10.1016/j.jhep.2012.11.042 (2013).
30. Kodama, T. et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121, 3343-3356, https://doi.org/10.1172/jci44957 (2011).
31. Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-Triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, https://doi.org/10.1172/jci.insight.92902 (2017).
32. Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 66, 724-733, https://doi.org/10.1016/j.jhep.2016.12.005 (2017).
33. Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286-2298, https://doi.org/10.1002/hep.26939 (2014).
34. Panasiuk, A., Dzieciol, J., Panasiuk, B. & Prokopowicz, D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-Alcoholic fatty liver disease. World J Gastroenterol 12, 6198-6202 (2006).
35. Farrell, G. C. et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 24, 443-452, https://doi.org/10.1111/j.1440-1746.2009.05785.x (2009).
36. Yang, Z., Zhang, Y., Kemper, J. K. & Wang, L. Cross-regulation of protein stability by p53 and nuclear receptor SHP. PLoS One 7, e39789, https://doi.org/10.1371/journal.pone.0039789 (2012).
37. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626, https://doi.org/10.1016/j.cell.2008.03.025 (2008).
38. Poyurovsky, M. V. et al. The C terminus of p53 binds the N-Terminal domain of MDM2. Nat Struct Mol Biol 17, 982-989, https://doi.org/10.1038/nsmb.1872 (2010).
39. Montero, J., Dutta, C., van Bodegom, D., Weinstock, D. & Letai, A. p53 regulates a non-Apoptotic death induced by ROS. Cell Death Differ 20, 1465-1474, https://doi.org/10.1038/cdd.2013.52 (2013).
40. Tomita, K. et al. p53/p66Shc-mediated signaling contributes to the progression of non-Alcoholic steatohepatitis in humans and mice. J Hepatol 57, 837-843, https://doi.org/10.1016/j.jhep.2012.05.013 (2012).
41. Wang, Y. D. et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol 29, 322-331, https://doi.org/10.1210/me.2014-1225 (2015).
42. Gai, Z. et al. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep 7, 9815, https://doi.org/10.1038/s41598-017-10168-6 (2017).
43. Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D. & Gonzalez, F. J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118-129, https://doi.org/10.1002/hep.25630 (2012).
44. Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97-101, https://doi.org/10.1038/nature12347 (2013).
45. Tomita, K. et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59, 154-169, https://doi.org/10.1002/hep.26604 (2014).
46. Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62, S25-37, https://doi.org/10.1016/j.jhep.2015.02.023 (2015).
47. Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53, 1723-1737, https://doi.org/10.1194/jlr.R024794 (2012).
48. Mari, M., Morales, A., Colell, A., Garcia-Ruiz, C. & Fernandez-Checa, J. C. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11, 2685-2700, https://doi.org/10.1089/ars.2009.2695 (2009).
49. Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 45, 55-58, https://doi.org/10.1097/MCG.0b013e3181dd1348 (2011).